Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03771586 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects

A Phase 1 study, sponsored by Supernus Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT03771586: Completed Phase 1 study, sponsored by Supernus Pharmaceuticals.

NCT03771586 is a Phase 1 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03771586, a Phase 1 study, has completed, sponsored by Supernus Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

This study is a phase 1, double-blind, placebo-controlled crossover study of single, oral dose of SAGE-718 using a ketamine challenge, to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects

Interventions

  • DRUG Placebo
  • DRUG SAGE-718

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-09-24
Est. Completion 2019-01-02
Phase Phase 1
Supernus Pharmaceuticals

57 total trials

What the finished NCT03771586 record still lists

NCT03771586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT03771586 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03771586 about?

NCT03771586 is a clinical study titled "A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects". This study is a phase 1, double-blind, placebo-controlled crossover study of single, oral dose of SAGE-718 using a ketamine challenge, to evaluate the electrophysiology, safety, tolerability, and pharmacokinetics in healthy subjects

What is the current status of trial NCT03771586?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-09-24. Estimated completion is 2019-01-02.

What interventions are being tested in trial NCT03771586?

The interventions under investigation include: Placebo (DRUG), SAGE-718 (DRUG).

Who is sponsoring clinical trial NCT03771586?

This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03771586's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03771586, the US trial registry maintained by the National Library of Medicine. NCT03771586 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.